Lilly's weight-loss drug Zepbound found to treat sleep apnea
INDIANAPOLIS, Indiana: This week, Eli Lilly said that after conducting two late-stage trials, its weight-loss drug Zepbound has been proven to reduce sleep apnea episodes, paving the way for its expanded use.
The company added that the GLP-1 drug cut the frequency of irregular breathing episodes associated with a common sleep-related disorder by as much as 63 percent across the two studies.
Popular GLP-1